Meetings of the California Initiative to Advance Precision Medicine - Office of Planning and Research

Opportunities

Notice of Intent to Publish a Funding Opportunity Announcement for Collaborative Partnership between Research Centers in Minority Institutions and Alcohol Research Centers

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) intends to re-issue the FOA RFA-AA-20-010. This reissue is to facilitate planning and implementation of collaborative partnerships between Research Centers in Minority Institutions (RCMI) and institutions with extensive alcohol research programs, including NIAAA-funded alcohol research centers and consortia (ARC). The long-range goal of the collaborative partnership program between RCMI and ARC is to strengthen the alcohol research capacity, develop research expertise in biomedical and clinical fields to identify, characterize, and reduce adverse health effects due to alcohol use and misuse.

Understanding and Targeting the Pathophysiology of Youth-onset Type 2 Diabetes – Clinical Centers

The purpose of this FOA is to create a clinical consortium to recruit a cohort of early pubertal youth at risk for developing type 2 diabetes and study them through puberty. The ultimate goal of this undertaking will be to 1) develop more precise prediction of which individuals are truly at risk for developing youth-onset T2D and identify determinants of progression from prediabetes to T2D so that, ultimately, targeted prevention approaches can be developed and tested; and 2) increase understanding of the physiologic drivers of youth-onset T2D to guide development of more effective strategies to achieve glycemic control and preserve beta cell function.

Cancer Target Discovery and Development

This FOA solicits applications for U01 cooperative agreement research projects addressing the areas outlined above. The proposed projects should use a combination of state-of-the-art high throughput informatic and experimental approaches to: characterize and validate novel cancer targets; develop precise perturbagens that can affect the proposed targets of cancer treatments and define the mechanism(s) of action; identify molecular markers that can meaningfully predict responses or resistance to anticancer therapies and develop algorithms that can be applied to predict responses to treatments and/or define more precise treatment modalities.

HEAL Initiative: Planning Studies for Initial Analgesic Development (Small Molecules and Biologics)

The goal of this funding opportunity is to solicit Analgesic Development R61 applicants that propose 2-year exploratory/planning awards that are expected to enable a future application for RFA-NS-21-015 HEAL Initiative: Team Research – for Initial Translational Efforts in Non-addictive Analgesic Development. The application must include a plan for developing a strong research team, as well as a strategy to collect preliminary data linking putative therapeutic targets to the proposed pain indication.

BRAIN Initiative: New Technologies and Novel Approaches for Recording and Modulation in the Nervous System

This funding opportunity seeks applicants for proof-of-concept testing and development of new technologies and novel approaches for recording and modulation of cells and networks to enable transformative understanding of dynamic signaling in the central nervous system. Proposed technologies should be compatible with experiments in behaving animals, validated under in vivo experimental conditions, and capable of reducing major barriers to conducting neurobiological experiments and making new discoveries about the central nervous system.

For more information about this content, please contact:

Megan Varvais

Megan Varvais is the Communication Specialist for the California Initiative to Advance Precision Medicine. She coordinates CIAPM's web content.

Megan.Varvais@opr.ca.gov